Kokilaksha

Kokilaksha (Asteracantha longifolia / Hygrophila auriculata)

1. Identity: Botanical Names, Natural Source, and Common Forms

1.1 Botanical and Chemical Identity

Kokilākṣa (Sanskrit: कोकिलाक्ष) is the classical Sanskrit name for the medicinal plant identified as Astercantha longifolia Nees., a synonym of Hygrophila auriculata (Schumach.) Heine, belonging to the family Acanthaceae — the "acanthus" family of flowering plants — as recorded in verse 4.191–193 of the 13th-century Rājanighaṇṭu. The plant is also commonly referred to in the scientific literature under the synonyms Hygrophila spinosa T. Anders and Asteracantha longifolia (L.) Nees, all of which refer to the same botanical entity.

Asteracantha longifolia (L.) Nees, Acanthaceae, is the source of the Ayurvedic drug "Kokilaaksha" and the Unani drug Talimakhana. A. longifolia is described in Ayurvedic literature as Ikshura, Ikshugandha, and Kokilasha — meaning "having eyes like the Kokila or Indian Cuckoo."

Kokilākṣa is commonly known in Hindi as Tālmakhānā; in Bengali as Kuliākhāra; in Marathi as Talimkhānā; in Gujarati as Elkhāro; in Telugu as Nirugubbi; and in Tamil as Nirmūllī. In English-language botanical literature it is sometimes referred to simply as "Hygrophila" or "swamp weed."

1.2 Plant Description and Habitat

Hygrophila auriculata is an annual herb that grows to a height of 60 cm. The plant stem is square, hairy, and thicker at its nodes. The bark is dark brown, and the leaves are elliptic-lanceolate and hispid. White or pale lavender tubular flowers bloom axillary and are about 2–3 cm in length.

In Ayurvedic literature the plant is described as Ikshura, Ikshugandha, and Kokilasha — "having eyes like Kokila or the Indian cuckoo" — common in moist places on the banks of tanks, ditches, and paddy fields. It is believed to be indigenous to India from the Himalayas to Sri Lanka, Myanmar, Malaysia, and Nepal.

1.3 Plant Parts Used and Common Preparations

Roots, seeds, and even the whole plant are used in medicinal fields. Various formulations of Kokilaksha — including Swarasa (juice), Kalka (paste), Kwatha (decoction), Churna (powder), Bhasma (ash), Taila (oil), Ghrita (ghee), and many more — have been used as Vajikarana (aphrodisiac) and also in the treatment of Mootrakrichchha (dysuria), Ashmari (stone), Vatarakta (gout), Shotha (inflammation), and other diseases. A review screening 27 classical Ayurvedic texts found that, out of 103 formulations, Churna (powder) and Kwatha (decoction) are the most used preparations of Kokilaksha.

The plant is also used commercially as an ingredient in some over-the-counter (OTC) formulations used in liver disorders and those prescribed as general tonics.

---

2. Traditional and Historical Use

2.1 Ayurveda

The plant Kokilaksha (Asteracantha longifolia Nees.) is an annual herb utilized in Ayurveda and other Indian medical systems. It is a potential medicinal plant belonging to the Acanthaceae family, which has been employed effectively for its therapeutic potency across a wide spectrum of ailments. It is mentioned in Ayurvedic treatises like the Sushruta Samhita and the Charaka Samhita as a Rasayana, or rejuvenator.

The whole plant of Astercantha longifolia is used in traditional Ayurvedic medicine for the treatment of sexual disorders, inflammatory disorders, and urinary disorders. In classical literature, Kokilaksha has been assigned the properties Vrishya (aphrodisiac), Mutravirechaka (diuretic), Rasayana (rejuvenating), and Ashmaribhedaka (lithotriptic).

According to Ayurvedic pharmacological properties, Kokilaksha is sweet and bitter in taste, sweet in the post-digestive effect, and has cold potency. It alleviates Vata and Pitta. The seeds and plants are cold in potency and sweet mixed bitter in taste; the seeds are slimy, heavy, and tonic in nature.

Traditional Ayurvedic indications recorded across classical texts include: treatment of Vatarakta (gouty arthritis) and biliary stones — especially in the form of Kokilaksha kshara — and the seeds are proclaimed as best aphrodisiacs, said to improve sperm count and increase viscosity of semen. The drug is described as effective in Vata disorders, edema, calculi, thirst, and blood-borne disorders. The Kshar (alkaline ash preparation) is considered a best panacea for ascites and urinary stones.

Traditional dosage forms described in classical Ayurvedic texts include: decoction of the root given in a dose of 10 ml to treat jaundice and body swelling; powder of the seed given in a dose of 2–4 g with milk for impotence, low sperm count, and general debility; the ash (Kshara) prepared by burning the dried plant given with decoction of Tribulus terrestris to treat renal calculi; and the cold infusion of the seed given in a dose of 25–30 ml to treat hepatomegaly and abdominal bloating.

2.2 Unani Medicine

The Acanthaceae plant Asteracantha longifolia (L.) Nees is used to make the Ayurvedic medication "Kokilaaksha" and the Unani drug Talimakhana. In the Unani system, the seeds are considered a tonic for reproductive and general debility. The roots are described as bitter, sweet, thermogenic, emollient, stimulant, purgative, aphrodisiac, diuretic, emmenagogue, anthelmintic, febrifuge, and tonic. They are recorded as useful in vitiated conditions of Vatha and Pitta, constipation, nephropathy, strangury, dysmenorrhea, amenorrhea, elephantiasis, dropsy, neuropathy, ulcers, helminthiasis, fever, and delirium.

2.3 Siddha Medicine

In the Siddha system of medicine, male infertility is referred to as Aan Maladu and is traditionally managed through formulations aimed at enhancing reproductive vitality. One such classical polyherbal formulation is Vithuvagai Chooranam (VVC), widely used to improve semen quality, increase virility, and support male reproductive health. This formulation comprises ten ingredients, including Hygrophila auriculata, Mucuna pruriens, Curculigo orchioides, and Asparagus racemosus, all of which are rich in bioactive compounds known for their spermatogenic, aphrodisiac, antioxidant, anti-inflammatory, and immunomodulatory properties.

2.4 Folk and Ethnomedical Use

The medicinal plant Hygrophila auriculata, belonging to the Acanthaceae family and generally present in aquatic areas, is a rare and endemic species across multiple countries, used to treat various diseases and disorders. Extracts and bioactive compounds from the plant have been found in ethnomedicinal traditions to possess antimicrobial, anthelmintic, nephroprotective, hepatoprotective, antitumour, antidiabetic, antioxidant, haematopoietic, diuretic, anti-inflammatory, antipyretic, aphrodisiac, and anti-urolithiatic activities.

---

3. Key Phytochemical Constituents and Mechanisms of Action

3.1 Phytochemical Profile

The plant has been reported to contain flavonoids (apigenin, luteolin, ellagic acid, gallic acid, and quercetin), alkaloids (asteracanthine and asteracanthicine), triterpenes (lupeol, lupenone, hentricontane, and betulin), sterols (stigmasterol and asterol), minerals, amino acids, fatty acids, aliphatic esters, and essential oils.

The plant contains various groups of phytoconstituents, namely phytosterols, fatty acids, minerals, polyphenols, proanthocyanins, mucilage, alkaloids, enzymes, amino acids, carbohydrates, hydrocarbons, flavonoids, terpenoids, vitamins, and glycosides.

Pharmacognostic studies have identified over 20 phytochemical constituents, including alkaloids, flavonoids, and saponins. A validated HPLC study detected substantial quantities of quercetin and luteolin in hydroalcoholic extracts of H. spinosa: the hydroalcoholic extract of H. spinosa contains substantial quantities of quercetin (QR) and luteolin (LU), quantified at 17.0 mg/100 g and 17.4 mg/100 g, respectively.

Chemical investigations have revealed the presence of essential oils, fatty acids, waxy substances, gums, mucilage, alkaloids, sterols, and minerals including calcium, magnesium, potassium, iron, copper, zinc, manganese, cobalt, and chromium in different parts of the plant.

3.2 Mechanisms of Action

The pharmacological activities observed in laboratory research are attributed to several constituent classes, each with proposed mechanisms:

• Hepatoprotective mechanism: The herb has been reported to contain chemical constituents such as β-sitosterol and lupeol, both of which have been reported to have antipyretic and hepatoprotective activity. Antioxidant action — particularly through enhancement of glutathione and antioxidant enzyme systems — is considered a central mechanism.
• Antidiabetic/hypoglycemic mechanism: Asteracantha longifolia appears to increase insulin secretion, bringing glucose back to normal levels. The antidiabetic effect of leaf extracts may be due to increased release of insulin from the existing beta cells of the pancreas, similar to the effect observed after glibenclamide administration.
• Aphrodisiac/spermatogenic mechanism: A sterol-enriched (unsaponifiable) fraction from chloroform extract of the seeds of Hygrophila spinosa has been investigated for spermatogenic and aphrodisiac activity; an unsaponifiable fraction was evaluated for its ability to stimulate testosterone production using isolated rat Leydig cells in vitro.
• Anti-inflammatory mechanism: Ethanol and distilled water extracts of the plant exhibited significant anti-inflammatory activity, whereas potent analgesic activity was shown by petroleum ether and ethanol extracts.
• Haematopoietic mechanism: Petroleum ether extraction from Hygrophila auriculata increases WBC count significantly. A mixture of petroleum ether:chloroform extracts of the leaf significantly increases erythrocyte count and leukocyte count.

---

4. Scientific Evidence by Area of Use

Important framing note: All pharmacological studies reviewed for this article were conducted in vitro (cell-based) or in vivo in rodent models. No large-scale, registered randomized controlled trials (RCTs) in human subjects have been identified in the indexed literature for Kokilaksha as a single ingredient. Where human hypoglycemic activity has been referenced, the underlying study is a preliminary investigation. All evidence below should therefore be understood as preclinical, with evidence strength characterized accordingly.

4.1 Hepatoprotective Activity

Hygrophila auriculata (K. Schum) Heine (syn. Asteracantha longifolia Nees, Acanthaceae) was widely used in the Indian systems of medicine for the treatment of various liver ailments. This traditional use has attracted a substantial body of preclinical research.

A study published in the Journal of Pharmacy and Pharmacology (2003) and indexed on PubMed evaluated the aqueous extract of A. longifolia in mouse models of liver injury: overall results indicate that the aqueous extract of Asteracantha longifolia possesses hepatoprotective effects on CCl4- and paracetamol-induced hepatotoxicity in mice. The plant extract also increased the glutathione concentration of the liver significantly (P < 0.001). Histopathological studies also provided supportive evidence for results from the biochemical analysis with marked improvement in liver architecture being observed in the Asteracantha-treated groups. Pre-treatment showed better results than post-treatment in both hepatotoxic models.

A separate study published in the Journal of Ethnopharmacology (2006) examined root extracts: the hepatoprotective activity of the aqueous extract of the roots was studied on CCl4-induced liver toxicity in rats. The activity was assessed by monitoring liver function tests, including alanine transaminase, aspartate transaminase (AST), alkaline phosphatase (ALP), total protein, and total bilirubin. Hepatic tissues were also subjected to histopathological studies. The root extract was further studied for in vitro antioxidant activity using ferric thiocyanate (FTC) and thiobarbituric acid (TBA) methods.

The seeds are reported to be diuretic, aphrodisiac, and used prophylactically for curing asthma, jaundice, and liver ailments, and as an ingredient of at least 10 polyherbal formulations with established hepatoprotective action. The methanolic fraction of A. longifolia seeds reportedly inhibits thioacetamide- and paracetamol-induced toxic manifestations.

Evidence strength: Preclinical (rodent, in vitro) only. Multiple independent studies demonstrate consistent hepatoprotective signals across different plant parts (root, stem, seed) and extract types. No human clinical trials are available.

4.2 Anti-Tumor / Chemopreventive Activity

One published study aimed to evaluate the chemopreventive efficacy of the methanol fraction of Asteracantha longifolia seed extract against development of 2-acetylaminofluorene (2-AAF)-selected gamma-glutamyl transpeptidase (gamma-GT)-positive foci following diethylnitrosamine (DEN) initiation in rats. Treatment at doses of 200 and 400 mg/kg body weight of methanol extract of A. longifolia seeds on alternate days, subsequent to carcinogen treatment, for 6 weeks significantly reduced the incidence and size distribution of gamma-GT-positive foci and tumor formation. Administration of A. longifolia seeds significantly (P < 0.001) ameliorated the activities of antioxidant enzymes, glutathione peroxidase (GPx) and catalase (CAT), in a dose-dependent manner.

Evidence strength: Preclinical (rodent) only. Findings from an experimental hepatocarcinogenesis model are promising but cannot be extrapolated to humans without clinical investigation.

4.3 Hypoglycemic / Antidiabetic Activity

Human hypoglycemic action of Asteracantha longifolia was first reported in 1989. Treatment of streptozotocin-induced diabetic rats with ethanolic extracts from the aerial parts of H. auriculata at doses of 100 and 250 mg/kg for 3 weeks resulted in significant reductions in blood glucose, thiobarbituric acid reactive substances, and hydroperoxide in both the liver and kidney. This also boosted glutathione, glutathione peroxidase, glutathione S-transferase, and catalase levels to levels comparable to the control group.

Hygrophila auriculata has been shown to possess hypoglycemic activity in human subjects, according to one cited reference from 1989 (Fernando et al., Journal of Ethnopharmacology, 27:7–14). This reference constitutes the earliest — and apparently limited — human-subject evidence. The methodology and scale of this early study were preliminary.

Evidence strength: Predominantly preclinical. The sole human reference is a preliminary 1989 study. No modern RCTs are documented in the indexed literature.

4.4 Aphrodisiac and Spermatogenic Activity

Seeds of Hygrophila spinosa T. Ander (Acanthaceae) are traditionally used as an aphrodisiac and spermatogenic in the Indian System of Medicine. Preliminary phytochemical screening of the plant revealed the presence of alkaloids in seeds. As alkaloid fractions of several plants showed aphrodisiac and spermatogenic potential, experiments were designed to assess an alkaloid-enriched fraction of seeds for spermatogenic and aphrodisiac activity using in vitro and in vivo methods. The alkaloid-enriched fraction was prepared and assessed for spermatogenic activity using isolated rat Leydig cells in vitro. The fraction was further evaluated in vivo for spermatogenic and aphrodisiac potential using rats. Increase in weight of reproductive organs, biochemical evaluation of selected parameters, histological studies of testes, and sexual behavioral studies were selected as evaluation parameters for in vivo studies.

Plant extracts showed the ability to raise the development of mature spermatozoa, as witnessed in transverse section.

Evidence strength: Preclinical (in vitro and animal) only. Results demonstrate activity across multiple endpoints in animal models but have not been validated in human clinical trials.

4.5 Haematopoietic (Blood-Forming) Activity

Research referenced in multiple reviews documents haematopoietic activity. The plant is an important medicinal herb, widely distributed in India and used by local population for different medicinal purposes. It is also used commercially as an ingredient in some over-the-counter (OTC) formulations used in liver disorders and those prescribed as general tonic. A study by Pawar et al. (2010), published in the Journal of Ethnopharmacology, evaluated the erythropoietic activity of Asteracantha longifolia in rats, with results confirming blood-cell-forming properties in cyclophosphamide-induced bone marrow depression models.

Evidence strength: Preclinical (animal) only.

4.6 Diuretic Activity

Kokilaksha is used as a diuretic in Ayurvedic formulations. This traditional claim has been explored in animal pharmacology. A study by Ahmed et al. (2009) — "Preliminary studies on diuretic effect of Hygrophila auriculata (Schum) Heine in rats," published in the International Journal of Health Research — examined diuretic effects in rat models, providing supporting preclinical evidence.

Evidence strength: Preclinical (animal) only.

4.7 Nephroprotective Activity

Methanolic extract from aerial parts and ethanolic extract from the whole plant have been investigated against gentamycin- and cisplatin-induced renal nephrotoxicity models, respectively. The nephroprotective effects of the plant's leaf extracts have also been of interest. In the cisplatin nephrotoxicity study, in acute oral toxicity testing the extract was found to be safe up to a dose of 2000 mg/kg.

Evidence strength: Preclinical (animal) only.

4.8 Anti-inflammatory and Analgesic Activity

In the last four decades, various research teams have conducted experiments with the plant Hygrophila spinosa to screen the plant for hepatoprotective, anti-urolithiasis, diuretic, anti-hypertensive, antidiabetic, chemoprotective, and anticancer activities along with analgesic and anti-inflammatory activity.

Evidence strength: Preclinical (animal, in vitro) only.

4.9 Antioxidant Activity

The antioxidant activity of 70% ethanolic extracts of Asteracantha longifolia (aerial parts and roots) has been evaluated using four in vitro models: DPPH, nitric oxide (NO), hydrogen peroxide (H₂O₂), and ferric reducing antioxidant power (FRAP) assays. Multiple studies across different extract types and plant parts have demonstrated in vitro free-radical-scavenging capacity.

Evidence strength: In vitro only. Antioxidant capacity in laboratory assays does not directly translate to clinical benefit without human bioavailability and efficacy data.

---

5. Body Systems and Health Areas Associated with Kokilaksha

Based on the combined traditional and scientific literature, the following body systems are associated with Kokilaksha:

• Hepatobiliary system: The root and seeds are used in decoctions to manage jaundice and liver enlargement; hepatoprotective effects are documented in preclinical studies.
• Urinary/Renal system: Classical attributes include Mutravirechaka (diuretic) and Ashmaribhedaka (lithotriptic) properties. Nephroprotective activity has also been investigated preclinically.
• Reproductive system: Traditionally used to increase sexual vitality and male fertility; seeds are used to improve sperm count and motility; it is classified as a Vajikarana herb in Ayurveda.
• Musculoskeletal system: Kokilaksha is well appreciated in the treatment of Vatarakta (gouty arthritis).
• Haematopoietic system: The plant is known to possess haematopoietic activity.
• Metabolic / Endocrine system: The plant is known to possess hypoglycemic activity.
• Immune / General tonic: Classified in Ayurveda as a Rasayana (rejuvenating) herb, supporting general vitality and immunity.

---

6. Dosage Forms and Dosages Reported in Sources

6.1 Traditional Ayurvedic Dosages

The following dosages are as recorded in traditional Ayurvedic practice and reported in published literature — they do not represent clinically validated recommendations:

• Decoction of the root: given in a dose of 10 ml to treat jaundice and body swelling.
• Powder of the seed: given in a dose of 2–4 g with milk to treat impotence, low sperm count, and general debility.
• Cold infusion of the seed: given in a dose of 25–30 ml to treat hepatomegaly and abdominal bloating.
• Grinding the leaves into powder form or making a decoction: approximately 3–5 g of the powder or equivalent decoction protocols, documented for urinary support.

6.2 Dosages Used in Preclinical Studies

• In the experimental hepatocarcinogenesis study, doses of 200 and 400 mg/kg body weight of methanol extract of A. longifolia seeds on alternate days for 6 weeks were used in rats.
• In the antidiabetic study, ethanolic extracts from the aerial parts of H. auriculata were administered to streptozotocin-induced diabetic rats at doses of 100 and 250 mg/kg for 3 weeks.
• In the aphrodisiac/spermatogenic fraction study, the fraction was administered for 28 days to animals.
• In the cisplatin nephrotoxicity study, an acute oral toxicity study found the extract to be safe up to a dose of 2000 mg/kg in rodents.

No standardized human clinical dosage regimens have been established through controlled trials for any indication.

---

7. Safety Considerations

7.1 General Toxicity Data

Many animal studies suggest that seed as well as root Asteracantha longifolia extract is safe for oral administration at low and moderate doses, while the high dose of 500 mg/kg is not absolutely free from toxic effects.

In the acute toxicity study referenced in the cisplatin nephrotoxicity research, the extract was found to be safe up to a dose of 2000 mg/kg in rats (oral administration), suggesting a wide margin of safety at conventional doses in animal models.

7.2 Preservation and Handling

Preservation of Kokilaksha is difficult as it is affected by moisture very quickly; the seeds are hygroscopic and get infested very fast. This is a relevant quality consideration affecting the potency and shelf-life of preparations derived from the plant.

7.3 Pharmacological Interactions of Note

Given preclinical evidence of hypoglycemic activity (specifically, an apparent insulin secretagogue mechanism), the antidiabetic effect of leaf extracts may be due to increased release of insulin from the existing beta cells of the pancreas, similar to that observed after glibenclamide (antidiabetic drug) administration. This pharmacodynamic parallel raises a theoretical risk of additive hypoglycemia if co-administered with established antidiabetic drugs, though this has not been studied clinically.

The diuretic properties documented in preclinical studies also represent a theoretical consideration in the context of concurrent diuretic drug therapy, as additive effects on urinary output and electrolyte balance cannot be excluded.

7.4 Absence of Clinical Safety Data

No formal phase I safety trials, post-market surveillance studies, or case series documenting adverse effects in human populations have been identified in the indexed literature for Kokilaksha as a single-ingredient preparation. The absence of reported adverse events in the traditional use record, combined with the wide margin of safety demonstrated in acute rodent toxicity, provides limited indirect reassurance, but formal human safety characterization is lacking.

7.5 Regulatory and Pharmacopeial Status

The Ayurvedic Pharmacopoeia of India (API) is the legal document of standards for the quality of Ayurvedic drugs and substances; its six volumes list 395 medicinal plants that can be officially used for the preparation of single drugs. Kokilaksha / Asteracantha longifolia is listed in the Ayurvedic Pharmacopoeia of India, Part I, Volume II (Government of India, Ministry of AYUSH), providing official standardization parameters including physicochemical constants. Physical constants measured in pharmacognostic studies include total ash (not more than 9%) and water-soluble extractive (at least 20%). No equivalent monograph from the European Medicines Agency (EMA), European Pharmacopoeia, WHO Drug Monographs, or USP has been identified in the available literature.

---

8. Summary of Evidence

Kokilaksha (Asteracantha longifolia / Hygrophila auriculata) is a well-documented herb within the Ayurvedic, Unani, and Siddha traditions of the Indian subcontinent, with a documented history of use across multiple classical texts spanning at least several centuries. Extracts and bioactive compounds from the plant have been found to possess antimicrobial, anthelmintic, antitermite, nephroprotective, hepatoprotective, central nervous system protective, antitumour, antidiabetic, anticataract, antioxidant, haematopoietic, diuretic, antinociceptive, anti-inflammatory, antipyretic, antimotility, aphrodisiac, neuroprotection, anti-endotoxin, and anti-urolithiatic activities.

However, the overall scientific evidence base remains at the preclinical stage. A comprehensive review covering patents, clinical studies, analytical studies, and marketed formulations from the earliest found examples from 1887 to the end of 2017 identified a rich body of preclinical work but limited human clinical data. The hepatoprotective evidence is the most extensively replicated across independent laboratories. Human evidence is restricted to a single preliminary hypoglycemic study from 1989. Randomized controlled trials in human populations have not been reported in indexed literature for any indication. The transition from animal pharmacology to validated human therapeutics remains an open research priority for this plant.

References

• Chauhan NS, Dixit VK. "Asteracantha longifolia (L.) Nees, Acanthaceae: chemistry, traditional, medicinal uses and its pharmacological activities — a review." Revista Brasileira de Farmacognosia, 2010;20(5):812–817.
• Hewawasam RP, et al. "Protective effect of Asteracantha longifolia extract in mouse liver injury induced by carbon tetrachloride and paracetamol." Journal of Pharmacy and Pharmacology. 2003;55(10):1413–1418. PubMed.
• Ahmed S, et al. "Anti-tumor promoting activity of Asteracantha longifolia against experimental hepatocarcinogenesis in rats." Food and Chemical Toxicology. 2001;39(1):19–28. PubMed.
• Shanmugasundaram P, Venkataraman S. "Hepatoprotective and antioxidant effects of Hygrophila auriculata (K. Schum) Heine Acanthaceae root extract." Journal of Ethnopharmacology. 2006;104(1–2):124–128.
• Chauhan NS, Sharma V, Dixit VK. "Aphrodisiac and spermatogenic potential of alkaloidal fraction of Hygrophila spinosa T. Ander in rats." Journal of Ethnopharmacology. 2016.
• Chauhan NS, et al. "Aphrodisiac and spermatogenic potential of unsaponifiable fraction from seeds of Hygrophila spinosa T. Ander in rats." International Journal of Pharmaceutical Sciences and Research.
• Kshirsagar AD, Ingale KG, Vyawahare NS, Thorve VS. "Hygrophila spinosa: A comprehensive review." Pharmacognosy Reviews. 2010;4(8):167–171. PMC/PubMed.
• Protective effect of Hygrophila spinosa against cisplatin induced nephrotoxicity in rats. PMC/NIH.
• Sethiya NK, et al. "Ethnomedicinal, phytochemical and pharmacological updates on Hygrophila auriculata (Schum.) Hiene: an overview." Chinese Herbal Medicines. 2018.
• Wisdomlib.org — Kokilaksha: 9 definitions (Sanskrit Lexicon and Ayurvedic Nighantu sources).
• Nakum et al. "Screening of the used pattern of Kokilaksha (Asteracantha longifolia Nees.) containing formulations through Ayurved compendium." Research and Reviews: A Journal of Ayurvedic Science, Yoga and Naturopathy. 2023.
• Anti-tumor promoting activity of Asteracantha longifolia against experimental hepatocarcinogenesis in rats. ScienceDirect (Food and Chemical Toxicology, 2001).
• Review on pharmacological potential of Asteracantha longifolia. International Journal of Health Sciences. 2022.
• Nikam D, Mundada S, Mishra DS. "Kokilaksha: A potential Ayurvedic herb." International Journal of Research in Ayurveda and Pharmacy. 2012;3(6):780–782.
• Hygrophila auriculata (Schumach.) Heine: A review of Unani insights, ethnopharmacological uses, phytochemical profile, toxicological evaluation and modern pharmacological evidence. Journal of Population Therapeutics and Clinical Pharmacology. 2026.
• Gnanasri M, et al. "Antioxidant and antimicrobial activities along with physico-chemical studies of medicinal plant Hygrophila auriculata." Bulletin of Scientific Research. 2023;5(1):1–14.
• Unveiling the aerial mysteries of Hygrophila auriculata: Ethnomedicinal insights, phytochemical profiles and pharmacological potentials. International Journal of Research and Scientific Innovation (IJRSI). 2025.
• Kokilaksha Asteracantha longifolia: Uses, Research, Side Effects, Remedies. EasyAyurveda.com. 2017/2023.